

2023 Current Fiscal Year Report: Tick-Borne Disease Working Group

Report Run Date: 07/02/2025 04:07:36 AM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2023

3. Committee or Subcommittee

Tick-Borne Disease Working Group

3b. GSA Committee No.

2619

4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 08/10/2021 08/10/2023 12/13/2022

8a. Was Terminated During Fiscal Year? 8b. Specific Termination Authority 8c. Actual Term Date

Yes Section 2062 of the
21st Century Cures Act 12/13/2022

9. Agency Recommendation for Next Fiscal Year

Terminate

10a. Legislation Req to Terminate?

Yes

10b. Legislation Pending?

Not Applicable

11. Establishment Authority Statutory (Congress Created)

12. Specific Establishment Authority 13. Effective Date 14. Committee Type 14c. Presidential?

Section 2062 of the 21st
Century Cures Act 12/13/2016 Continuing No

15. Description of Committee Scientific Technical Program Advisory Board

16a. Total Number of Reports 1

16b. Report Date Report Title

12/13/2022 Tick-Borne Disease Working Group
2022 Report to Congress

Number of Committee Reports Listed: 1

17a. Open 3 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 3

Meetings and Dates

Purpose

Start

End

For this meeting, the TBDWG (1) reviewed the final draft of chapters for the report and (2) further discussed plans for developing the next report to the HHS Secretary and Congress on federal tick-borne activities and research, taking into consideration the 2018 and 2020 report. 10/04/2022 - 10/05/2022

For this meeting, the TBDWG will review and vote upon the third and final Report to Congress and the HHS Secretary. 10/24/2022 - 10/25/2022

The TBDWG met for the final time to take a final vote on chapters of the 2022 Report to Congress. 11/21/2022 - 11/21/2022

Number of Committee Meetings Listed: 3

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$10,337.04	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$142,376.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)	\$0.00	\$0.00
18d. Other (all other funds not captured by any other cost category)	\$161,220.00	\$0.00
18e. Total Costs	\$313,933.04	\$0.00
19. Federal Staff Support Years (FTE)	2.00	0.00

20a. How does the Committee accomplish its purpose?

The Working Group is charged to review ongoing activities and research related to tick-borne diseases conducted by HHS and other federal agencies, identify gaps in research and advances made, and provide a report to Congress and the HHS Secretary on its finding and recommendations every two years. The Working Group is also charged with soliciting input from States, localities, and nongovernmental entities, including organizations representing patients, health care providers, researchers, and industry. Subcommittees established by the Working Group research topic areas determined relevant to its charge and provide reports, including action items, for discussion and consideration by the Working Group for the biannual reports. The 2022 Report was delivered to Congress and the HHS Secretary in January 2023 and also posted on the HHS website for public access.

20b. How does the Committee balance its membership?

The Working Group comprises 14 members - seven federal members and seven public members. Federal members are required to consist of one or more representatives from the following HHS organizational components: Office of the Assistant Secretary for Health, Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, and such other agencies and offices of HHS and other individuals as the Secretary determines appropriate and beneficial to the functioning of the Working Group. Other federal members represent the Centers for Medicare and Medicaid Services, Department of Defense, and the United States

Department of Agriculture. Public members are required to represent the following categories: physicians and other health care providers with experience in diagnosing and treating tick-borne diseases; scientists or researchers with expertise; patients and their family members; and members of nonprofit organizations that advocate for patients with respect to tick-borne diseases.

20c. How frequent and relevant are the Committee Meetings?

The Working Group is required to meet not less than two times a year. Three meetings were held in FY23 and focused on topics and issues that supported development of the 2022 report to the HHS Secretary and Congress, taking into consideration the 2018 and 2020 report.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The 21st Century Cures Act (Public Law 114-255), Section 2062 Tick-Borne Diseases, authorized the HHS Secretary to establish a Tick-Borne Disease Working Group. In general, the Working Group is to provide expertise and to review all efforts within HHS related to all tick-borne diseases and examine agency research priorities in order to help ensure interagency coordination and minimize overlap. Every two years, the Working Group is required to submit a report to Congress and the HHS Secretary on its findings and any recommendations for improving the federal response to tick-borne diseases. The final report was delivered to Congress in January 2023.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

The authorizing legislation outlined a committee termination date of 12/13/2022 and in accordance with the legislation the committee was terminated on that date.

Designated Federal Officer

James J Berger Senior Advisor for Blood and Tissue Policy, Office of Infectious Disease and HIV/AIDS Policy

Committee Members	Start	End	Occupation	Member Designation
Beard, Ben	12/11/2017	12/13/2022	CDC	Regular Government Employee (RGE) Member
Bunnell, Rebecca	06/04/2019	12/13/2022	CMS	Regular Government Employee (RGE) Member
Dixon, Dennis	12/11/2017	12/13/2022	NIH	Regular Government Employee (RGE) Member
Embers, Monica	08/26/2021	12/13/2022	Associate Professor and Director, Vector borne Disease Research	Special Government Employee (SGE) Member
Goodreau, Holiday	08/26/2021	12/13/2022	Executive Director, LivLyme Foundation	Special Government Employee (SGE) Member
Hu, Linden	08/26/2021	12/13/2022	Professor of Microbiology and Medicine, Vice Dean for Research, Tufts University School of Medicine	Special Government Employee (SGE) Member
Maloney, Elizabeth	08/26/2021	12/13/2022	Physician	Special Government Employee (SGE) Member

Miller, Robert	08/26/2021	12/13/2022	USDA	Regular Government Employee (RGE) Member
Myers, Todd	08/26/2021	12/13/2022	FDA	Regular Government Employee (RGE) Member
Platt, Jennifer	08/26/2021	12/13/2022	Co-founder, Tick-Borne Conditions United	Special Government Employee (SGE) Member
Sood, Sunil	08/26/2021	12/13/2022	Infectious Disease Physician	Special Government Employee (SGE) Member
Stafford, Kirby	08/26/2021	12/13/2022	Chief Scientist and State Entomologist	Special Government Employee (SGE) Member
States, Leith	06/04/2019	12/13/2022	OASH	Regular Government Employee (RGE) Member
Zollner, Gabriela	08/26/2021	12/13/2022	DoD	Regular Government Employee (RGE) Member

Number of Committee Members Listed: 14

Narrative Description

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>

Effective grant making	<input type="checkbox"/>
Improved service delivery	<input checked="" type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input type="checkbox"/>

Outcome Comments

What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

Cost savings dependent on action taken on recommendations

What is the approximate Number of recommendations produced by this committee for the life of the committee?

75

Number of Recommendations Comments

The 2018 Report to the HHS Secretary and Congress included 28 recommendations, the 2020 Report included 27 recommendations, and the 2022 Report included 20 recommendations.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

2%

% of Recommendations Fully Implemented Comments

Many of the recommendations require long-term action which cannot be accomplished in a fiscal year.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

15%

% of Recommendations Partially Implemented Comments

Many of the recommendations require long-term action which cannot be accomplished in a fiscal year.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

HHS has the responsibility of ensuring the conduct of or support for epidemiological, basic, translational, and clinical research related to vector-borne diseases, including tick-borne diseases. Section 2062 of the 21st Century Cures Act mandated the Secretary of HHS establish the Tick-Borne Disease Working Group to review activities and research related to tick-borne diseases conducted by HHS and other federal agencies and provide a report to Congress and the HHS Secretary on its finding and recommendations every two years. The Working Group terminated in December 2022, six years after the date of enactment of the authorizing legislation. The public can view information on this Working Group at <https://www.hhs.gov/ash/advisory-committees/tickbornedisease/index.html>.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input checked="" type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

Not applicable

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

Not Applicable

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

Access Comments

N/A